Moreover, the expression levels of PPARα, PPARγ, FABP1, FABP4, and FABP5 were downregulated in GL22-treated xenograft tumors (Fig. 5b), indicating that GL22 exerted a significant anticancer effect against liver cancer in vivo mediated by PPAR–FABPs signaling pathway. This evidence concerns the gene PPARG and liver cancer.